New business committee targets R&D growth in periphery

The committee will be chaired by Israel Makov, the former CEO of Teva Pharmaceutical Industries Ltd., and include industry leaders, academics and government officials.

By MATTHEW KRIEGER
May 14, 2007 07:19
1 minute read.

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later Don't show it again

In an effort to increase work force participation, as well as the number of research and development companies operating in the country's periphery, Industry, Trade and Labor Minister Eli Yishai on Sunday introduced a committee charged with forming recommendations on how best these goals can be achieved. In addition, the panel will explore methods on how best to advance companies that operate in Israel's "traditional" industries, such as metal-works, textiles and electrical components, which have been overshadowed by the rise of Israel's hi-tech sector. "We are looking to close the gaps between companies that are based in the middle of the country and those in outlying areas, as well as increasing the numbers of skilled workers in those peripheral areas, in addition to advancing the output of our traditional manufacturers," said Yishai. The committee, which was expected to formulate concrete recommendations within the next three months, will be chaired by Israel Makov, the former CEO of Teva Pharmaceutical Industries Ltd., and include industry leaders, academics and government officials. Among the committee's stated objectives is the proposal of solutions on advancing the level of investment in "traditional" industry, to oversee the cooperation of various governmental offices and research institutes in advancing periphery-based biotechnology and diversified energy companies and to provide guidance to increase the number of research and development companies in the country's outlying areas.

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS